in ZOSYN
What it isExtended-spectrum penicillin, given with tazobactam; hospital-acquired and intra-abdominal infection.
Why this oneVery broad cover including Pseudomonas and anaerobes in one agent.
What limits itAcute kidney injury when combined with vancomycin. It causes falsely positive galactomannan; no MRSA cover.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Serious infections (septicemia, nosocomial pneumonia, intra-abdominal, gynecologic, skin/soft-tissue) | Adult | 12-18 g/day IV (200-300 mg/kg/d) divided q4-6h | 12-18 g/day IV | 24 g/day |
| Complicated urinary tract infection | Adult | 8-16 g/day IV (125-200 mg/kg/d) divided q6-8h | 8-16 g/day IV | 24 g/day |
| Uncomplicated UTI; most community-acquired pneumonia | Adult | 6-8 g/day IM or IV (100-125 mg/kg/d) divided q6-12h | 6-8 g/day | 24 g/day |
| Uncomplicated gonorrhea | Adult | 2 g IM once (with probenecid 1 g PO 30 min prior) | Single dose | 2 g x1 |
| Surgical prophylaxis (intra-abdominal, hysterectomy, cesarean) | Adult | 2 g IV just prior to surgery (cesarean: after cord clamped), then 2-3 procedure-specific doses | Stop within 24 h post-op |
Renal CrCl 20-40: serious infections 12 g/d (4 g q8h), complicated UTI 9 g/d (3 g q8h); CrCl <20: serious 8 g/d (4 g q12h), UTIs 6 g/d (3 g q12h); hemodialysis: max 6 g/d (2 g q8h) plus 1 g after each dialysis
Hepatic Undefined (in combined renal failure + hepatic insufficiency, guide dosing by serum piperacillin levels)
Usual course 7-10 days (gynecologic 3-10 days); pediatric <12 yr dosing not established
Pregnancy Category B — animal studies show no fetal harm; no adequate human studies; use only if clearly needed.
Lactation Excreted in low concentrations in human milk; use caution in nursing mothers.
NO BOXED WARNINGS
Principal riskNephrotoxicity with vancomycin; false-positive galactomannan
Cost, est. cash$2,000–$30,000+/dose or month
Generic entry2009
Legacy pregnancy categoryUnknown / historical label unavailable
Defining liabilitySerious infection and infusion/injection reactions; immune complications vary by molecular target.
